miR-30b-5p suppresses prostate cancer progression by targeting FLVCR1 through the cAMP/PKA/CREB pathway.
0/5 보강
APA
Shi D, Tang Y, et al. (2026). miR-30b-5p suppresses prostate cancer progression by targeting FLVCR1 through the cAMP/PKA/CREB pathway.. Scientific reports. https://doi.org/10.1038/s41598-026-50576-1
MLA
Shi D, et al.. "miR-30b-5p suppresses prostate cancer progression by targeting FLVCR1 through the cAMP/PKA/CREB pathway.." Scientific reports, 2026.
PMID
42045322 ↗
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (5)
- Epstein-Barr Virus Hijacks Redox Signaling via Glutathione Peroxidase 4 to Sustain Latency and Drive Gastric Cancer Progression.
- Quantitative analysis of enhanced CT in predicting microvascular invasion and pathological grading of hepatocellular carcinoma.
- Penile Ulcerations in a Patient with Acute Promyelocytic Leukemia.
- Socioeconomic inequalities and dynamic changes in sex differences in lifetime risks of peptic ulcer disease.
- Identifying potential mechanisms of circadian rhythm-related gene marker prognosis, immune infiltration, and melatonin intervention in thyroid cancer based on bioinformatics and network pharmacology.
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- Prostate Cancer Care for Men with an Intellectual Disability: A Population-based Cohort Study of Symptoms, Diagnosis, Treatment, and Survival.
- Association between polygenic risk scores and cardiovascular events in prostate cancer patients receiving androgen deprivation therapy in Han Chinese.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Impact of Comorbidities on Clinical Outcomes and Quality of Life of Patients With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2-) Advanced Breast Cancer Treated With Palbociclib in the POLARIS Study.
- The role of disulfidptosis-driven tumor microenvironment remodeling in pancreatic cancer progression.
- Balancing safety and efficacy of Bendamustine plus anti CD20 regimens in elderly patients (> 70 y) with follicular lymphoma: a tertiary academic center experience.